


PHARMACEUTICAL 2022

Esperion Therapeutics Inc. Rank 418 of 466





ESPERION[®]



PHARMACEUTICAL 2022

ESPERION

Esperion Therapeutics Inc. Rank 418 of 466

The relative strengths and weaknesses of Esperion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Esperion Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 13% points. The greatest weakness of Esperion Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 194% points.

The company's Economic Capital Ratio, given in the ranking table, is -127%, being 205% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	328,972
Cost of Goods Sold	0
Intangible Assets	56
Liabilities, Current	73,352
Liabilities, Non-Current	1,158
Other Assets	51,898
Other Compr. Net Income	-31
Other Expenses	60,570
Other Liabilities	504,024
Other Net Income	3,975
Other Revenues	78,447
Property and Equipment	664
Research and Development	105,975
Selling, General and Administrative Expense	184,985

Output Variable	Value in 1000 USD
Assets	381,590
Liabilities	578,534
Expenses	351,530
Revenues	78,447
Stockholders Equity	-196,944
Net Income	-269,108
Comprehensive Net Income	-269,124
Economic Capital Ratio	-127%

